| Editorial | ||||||||||||||||||||||||||||||
J Med Allied Sci. 2019; 9(1): 1-2 doi: 10.5455/jmas.28485 Advancements in immunotherapy: A paradigm shift in cancer treatment Aleem Ahmed Khan.
| ||||||||||||||||||||||||||||||
| REFERENCES |
| 1. Tellinghuisen TL and Lindenbach BD. Reverse transcription PCR-based sequence analysis of hepatitis C virus replicon RNA. Method Mol Biol (Clifton, NJ). 2009; 510, 165. [DOI via Crossref] [Pubmed]
2. Madigan MT, Martinko JM, Dunlap PV and Clark DP. Brock Biology of microorganisms 12th edn. International Microbiology. 2008; 11, 65-73. 3. Bullock GC, Bruns DE and Haverstick DM. Hepatitis C genotype determination by melting curve analysis with a single set of fluorescence resonance energy transfer probes. Clin Chem. 2002; 48(12), 2147. [Pubmed] 4. Dryer PD, Limketkai BN, Martin CM, Ma G, Sherman KE, Taylor LE et al. Screening for hepatitis C virus non-nucleotide resistance mutations in treatment-naive women. J Antimicrob Chemoth. 2009. [DOI via Crossref] [Pubmed] [PMC Free Fulltext] 5. Knipe D, Howley P, Griffin D, Lamb R, Martin M, Roizman B et al. Fields virology, vol. 1. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins. 2007. 6. Charavay C, Crisan D, Grando D, Geourjon C, Penin F, Del�age G et al. The European Hepatitis C Virus database. 2008. 7. Barril G, Castillo I, Arenas MD, Espinosa M, Garcia-Valdecasas J, Garcia-Fernandez N, et al. Occult hepatitis C virus infection among hemodialysis patients. J AM Soc Nephro. 2008; 19(12), 2288. [DOI via Crossref] [Pubmed] [PMC Free Fulltext] 8. Menegazzi P, Reho E, Ulivi M, Varnier OE, Lillo FB and Tagliaferro L. Rapid and accurate quantification of different HCV genotypes by LightCycler Real Time PCR and direct sequencing of HCV amplicons. New Microbiol. 2008; 31, 181-187. [Pubmed] 9. Cook L, Sullivan KW, Krantz EM, Bagabag A and Jerome KR. Multiplex real-time reverse transcription-PCR assay for determination of hepatitis C virus genotypes. J clin Microbiol. 2006; 44(11), 4149. [DOI via Crossref] [Pubmed] [PMC Free Fulltext] 10. Lindh M and Hannoun C. Genotyping of hepatitis C virus by Taqman real-time PCR. J Clin Virol. 2005; 34(2), 108-114. [DOI via Crossref] [Pubmed] 11. Hartwell D and Shepherd J. Pegylated and non-pegylated interferon-alfa and ribavirin for the treatment of mild chronic hepatitis C: A systematic review and meta-analysis. Int J Technol Assess. 2009; 25(01), 56-62. [DOI via Crossref] [Pubmed] 12. Alfaresi, M. and Elkoush, A. Determination of hepatitis C virus genotypes by melting-curve analysis of quantitative polymerase chain reaction products. Indian J Med Microbi. 2007; 25(3), 249. [DOI via Crossref] [Pubmed] 13. Rolfe KJ, Wreghitt TG, Alexander G and Curran MD. A real-time Taqman method for hepatitis C virus genotyping and methods for further subtyping of isolates. Method Mol Biol (Clifton, NJ). 2009; 510, 55. [DOI via Crossref] [Pubmed] 14. Martro E, Gonzalez V, Buckton AJ, Saludes V, Fernandez G, Matas L et al. Evaluation of a new assay for hepatitis C virus (HCV) genotyping targeting both 5'NC and NS5b genomic regions, in comparison with reverse hybridization and sequencing methods. J Clin Microbiol. 2007. [Pubmed] [PMC Free Fulltext] 15. Omrani MD and Ansari MHK. Hepatitis C Virus Genotyping by Melting Curve Analysis in West Azerbaijan, Northwest of Iran. Hepatitis Monthly. 2009; 9(2), 133-136. |
| How to Cite this Article |
| Pubmed Style Aleem Ahmed Khan. Advancements in immunotherapy: A paradigm shift in cancer treatment. J Med Allied Sci. 2019; 9(1): 1-2. doi:10.5455/jmas.28485 Web Style Aleem Ahmed Khan. Advancements in immunotherapy: A paradigm shift in cancer treatment. https://jmas.in/?mno=28485 [Access: January 12, 2023]. doi:10.5455/jmas.28485 AMA (American Medical Association) Style Aleem Ahmed Khan. Advancements in immunotherapy: A paradigm shift in cancer treatment. J Med Allied Sci. 2019; 9(1): 1-2. doi:10.5455/jmas.28485 Vancouver/ICMJE Style Aleem Ahmed Khan. Advancements in immunotherapy: A paradigm shift in cancer treatment. J Med Allied Sci. (2019), [cited January 12, 2023]; 9(1): 1-2. doi:10.5455/jmas.28485 Harvard Style Aleem Ahmed Khan (2019) Advancements in immunotherapy: A paradigm shift in cancer treatment. J Med Allied Sci, 9 (1), 1-2. doi:10.5455/jmas.28485 Turabian Style Aleem Ahmed Khan. 2019. Advancements in immunotherapy: A paradigm shift in cancer treatment. Journal of Medical and Allied Sciences, 9 (1), 1-2. doi:10.5455/jmas.28485 Chicago Style Aleem Ahmed Khan. "Advancements in immunotherapy: A paradigm shift in cancer treatment." Journal of Medical and Allied Sciences 9 (2019), 1-2. doi:10.5455/jmas.28485 MLA (The Modern Language Association) Style Aleem Ahmed Khan. "Advancements in immunotherapy: A paradigm shift in cancer treatment." Journal of Medical and Allied Sciences 9.1 (2019), 1-2. Print. doi:10.5455/jmas.28485 APA (American Psychological Association) Style Aleem Ahmed Khan (2019) Advancements in immunotherapy: A paradigm shift in cancer treatment. Journal of Medical and Allied Sciences, 9 (1), 1-2. doi:10.5455/jmas.28485 |
| |
|
Copyright © 2023 Journal of Medical and Allied Sciences All Rights Reserved. Subject to change without notice from or liability to Journal of Medical and Allied Sciences. For best results, please use Internet Explorer or Google Chrome |
Contact InformationBy regular mail/speed post/courier Dr. Nazia Uzma By email: editorialoffice@jmas.in By phone: +91 40 24340225, 24340129 By fax: +91 40 24340235 |
